NDA 207103 · Pfizer
Ibrance
Palbociclib · Oral · Kinase Inhibitor
NovelBreakthrough therapyAccelerated approvalPriority reviewLast checked: Nov 19, 2026Latest source record: Jun 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Feb 3, 2015
Approved uses
11
Original approval plus efficacy supplements
Registered trials
355
45 Phase 3, 62 recruiting
FAERS reports
95,562
50,805 serious, 10,701 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 2, 2026.
IBRANCE is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy. ( 1.1 ) • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, following recurrence on or after completing adjuvant endocrine therapy. ( 1.1 ) • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2 positive locally advanced or metastatic breast cancer following induction treatment. ( 1.2 ) 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurrence on or after completing adjuvant endocrine therapy. 1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or...
Mechanism: Palbociclib is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Cyclin D1 and CDK4/6 are downstream of signaling pathways which lead to cellular proliferation. In vitro, palbociclib reduced cellular proliferation of estrogen receptor (ER)-positive breast cancer cell lines by blocking progression of the cell from G1 into S phase of the cell cycle. Treatment of breast cancer cell lines with the combination of palbociclib and antiestrogens leads to decreased retinoblastoma (Rb) protein phosphorylation resulting in reduced E2F expression and signaling, and increased growth arrest compared...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 24, 2026 Supplement 24 · Efficacy Breakthrough therapyLetterLabel
- Sep 16, 2025 Supplement 23 · Efficacy LabelLetter
- Apr 23, 2025 Supplement 20 · Efficacy LabelLetter
- Sep 6, 2023 Supplement 17 · Efficacy LetterLabel
- Dec 13, 2022 Supplement 15 · Efficacy LabelLetter
- Sep 9, 2019 Supplement 11 · Efficacy LetterLabel
- Apr 4, 2019 Supplement 8 · Efficacy Breakthrough therapyLabelLetterReview
- Feb 6, 2018 Supplement 7 · Efficacy LabelLetter
- Mar 31, 2017 Supplement 4 · Efficacy · priority review Breakthrough therapyLetterLabelReview
- Feb 19, 2016 Supplement 2 · Efficacy · priority review Breakthrough therapyReviewLetterLabel
- Feb 3, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelSummary ReviewReview
3 products under this application
- IBRANCE · PALBOCICLIB 125MG · CAPSULE, ORAL · Prescription
- IBRANCE · PALBOCICLIB 75MG · CAPSULE, ORAL · Prescription
- IBRANCE · PALBOCICLIB 100MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Palbociclib" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- PALbociclib CoLlaborative Adjuvant StudyPivotal-lookingActive, not recruiting
Alliance Foundation Trials, LLC.Academic, hospital or other
NCT02513394 · 5,796 participants · Start Aug 2015 · Primary completion Nov 2020
Drug: Palbociclib; Standard Adjuvant Endocrine Therapy · For: Breast Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Phoenix, Arizona · 437 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
National Cancer Institute (NCI)NIH
NCT03155620 · 1,377 participants · Start Jul 31, 2017 · Primary completion Mar 31, 2025
Drug: Ensartinib; Erdafitinib and 11 more · For: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma and 42 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Mesa, Arizona · 172 sites in all
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseasePivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04711252 · 1,371 participants · Start Jan 28, 2021 · Primary completion Jun 26, 2026
Drug: AZD9833; Anastrozole and 4 more · For: ER-Positive HER2-Negative Breast Cancer
Sites: Mobile, Alabama; Springdale, Arkansas; Harbor City, California · 263 sites in all
- A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and SurgeryPivotal-lookingCompleted
GBG Forschungs GmbHAcademic, hospital or other
NCT01864746 · 1,250 participants · Start Oct 30, 2013 · Primary completion Aug 24, 2020
Drug: Palbociclib PD-0332991; Placebo · For: Breast Cancer; Hormonreceptor Positive; Her2-normal and 2 more
Sites: Pittsburgh, Pennsylvania; Newcastle, Australia; Vienna, Austria · 11 sites in all
- Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast CancerPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07005557 · 1,244 participants (planned) · Start Jun 15, 2025 · Primary completion May 15, 2030
Drug: Chemotherapy; CDK4/6 Inhibitor and 1 more · For: Breast Cancer; Adjuvant Therapy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue15,790
- white blood cell count decreased11,486
- neoplasm progression10,612
- nausea8,591
- death8,004
- neutropenia6,803
- alopecia6,384
- diarrhoea6,015
- asthenia3,823
- off label use3,677
- pain3,509
- decreased appetite3,508
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 14 |
| 2015 | 2,602 |
| 2016 | 5,940 |
| 2017 | 8,621 |
| 2018 | 9,067 |
| 2019 | 11,019 |
| 2020 | 12,869 |
| 2021 | 10,117 |
| 2022 | 12,585 |
| 2023 | 10,007 |
| 2024 | 6,069 |
| 2025 | 4,727 |
| 2026 | 1,918 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Apr 22, 2026
Ibrance, Capsule, 100 mg (NDC 0069-0188-21). Discontinuation of the manufacturing of the capsule presentation. 100 mg Tablet NDC 0069-0486-03 will continue to be manufactured.
To Be Discontinued · updated Apr 22, 2026
Ibrance, Capsule, 75 mg (NDC 0069-0187-21). Discontinuation of the manufacturing of the capsule presentation. 75 mg Tablet NDC 0069-0284-03 will continue to be manufactured.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ibrance (Palbociclib)
2024 spending
$2.04B
Beneficiaries
15,923
131,537 claims
Per beneficiary
$127,804
$744.24 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,108,937,188 |
| 2021 | $1,891,416,132 |
| 2022 | $1,948,323,854 |
| 2023 | $2,020,903,604 |
| 2024 | $2,035,022,061 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.
Hurvitz SA, Layman RM, Curigliano G, et al. · J Clin Oncol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.
Turner NC, Im SA, Saura C, et al. · N Engl J Med 2024 · Clinical Trial, Phase II, Comparative Study
- Palbociclib and Letrozole in Advanced Breast Cancer.
Finn RS, Martin M, Rugo HS, et al. · N Engl J Med 2016 · Clinical Trial, Phase III, Multicenter Study
- First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.
Bidard FC, Mayer EL, Park YH, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.
Jhaveri KL, Im SA, Saura C, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.
Wedam S, Narayan P, Gittleman H, et al. · J Clin Oncol 2025 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.